Transgenic organs and xenotransplants.

Area of Science:

• Transplantation immunology
• Regenerative medicine
• Biotechnology

Background:

• Solid organ transplantation is limited by human donor organ scarcity.
• Irreversible organ failure and specialized cell loss (e.g., pancreatic cells) drive demand for alternatives.
• Xenotransplantation emerged as a potential solution in the 1990s due to organ shortages.

Purpose of the Study:

• To review immunological and non-immunological barriers in xenotransplantation.
• To explore strategies for overcoming these barriers, focusing on genetically modified pigs.
• To assess the potential of cell transplantation, like pancreatic islets, in xenografts.

Main Methods:

• Review of existing xenotransplantation literature and clinical studies.
• Analysis of challenges in xenograft survival and immune rejection.
• Examination of genetic modification techniques in donor animals (pigs).
• Evaluation of cell transplantation outcomes (e.g., pancreatic islets).

Main Results:

• Early xenotransplantation studies (non-human primates) showed limited success (days to months survival).
• Significant immunological and non-immunological barriers persist in xenotransplantation.
• Genetically modified pigs show promise for overcoming rejection.
• Pancreatic islet xenotransplantation in primates has yielded encouraging results.

Conclusions:

• Xenotransplantation faces substantial immunological and non-immunological hurdles.
• Genetic modification of donor animals, especially pigs, is a key strategy.
• Cell transplantation, like pancreatic islets, shows hopeful outcomes.
• Xenotransplantation has the potential to become a clinical reality, addressing organ and cell shortages.